BridgeMD
New treatment option for Chronic Non-specific Low Back Pain
Official title Effect of VR-MBCT in Chronic Nonspecific Low Back Pain
ClinicalTrials.gov ID: NCT07589790
What this study is testing
- What it's testing
- This is a multi-center, prospective, open-label randomized controlled trial evaluating the efficacy and safety of virtual reality-based mindfulness-based cognitive therapy (VR-MBCT) as an adjunct to usual care in adults with chronic nonspecific low back pain (CNLBP). A total of 214 participants aged 20-70 years with pain duration ≥3 months and average back pain bothersomeness ≥4 (0-10 scale) will be enrolled from three hospitals in China and randomized 1:1 to an 8-week VR-MBCT intervention group or a waitlist usual care control group.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 70
You may be able to join if
- Patients who meet the following criteria will be included:
- Diagnosed with CNLBP according to standard criteria (3), with pain duration ≥3 months.
- Aged 20-70 years (inclusive), regardless of sex.
- Average self-reported back pain bothersomeness ≥4(scale, 0-10) in the past week.
- Provided informed consent and family members will be informed of the study as support persons.
You likely can't join if
- Coexisting pain conditions that may interfere with the assessment of CNLBP
- Severe neurological or psychiatric disorders (e.g., unstable epilepsy, psychosis, dementia)
- Severe psychiatric comorbidities (e.g., active suicidal ideation, severe depression requiring antidepressant medication)
- History of substance abuse (including alcohol or drugs) in the past year
- History of accidents or injuries related to back pain in the past year
- Severe visual impairment, vertigo, or history of VR-induced motion sickness precluding safe VR use
See the full eligibility criteria
- Patients who meet the following criteria will be included:
- Diagnosed with CNLBP according to standard criteria (3), with pain duration ≥3 months.
- Aged 20-70 years (inclusive), regardless of sex.
- Average self-reported back pain bothersomeness ≥4(scale, 0-10) in the past week.
- Provided informed consent and family members will be informed of the study as support persons.
- Coexisting pain conditions that may interfere with the assessment of CNLBP
- Severe neurological or psychiatric disorders (e.g., unstable epilepsy, psychosis, dementia)
- Severe psychiatric comorbidities (e.g., active suicidal ideation, severe depression requiring antidepressant medication)
- History of substance abuse (including alcohol or drugs) in the past year
- History of accidents or injuries related to back pain in the past year
- Severe visual impairment, vertigo, or history of VR-induced motion sickness precluding safe VR use
- Inability to communicate effectively to express subjective feelings.
The study team makes the final eligibility decision.
Where it's taking place
- Suzhou, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Suzhou, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.